Epithelial dysfunction, respiratory infections and asthma: the importance of immunomodulation. A focus on OM-85

Expert Review of Respiratory Medicine

Volumn , Issue , 2020, Pages

  Cardinale, Fabio ^a   Lombardi, Enrico ^b   Rossi, Oliviero ^c   Bagnasco, Diego ^d   Bellocchi, Aldo ^e   Menzella, Francesco ^f  

^a POLICLINICO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d Unità di Malattie Dell apparato Respiratorio   (Italy)

^e Pneumology Unit ^*  (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

asthma; COPD; epithelium; immunomodulation; OM 85; respiratory infections

Indexed keywords

BACTERIUM LYSATE; BIOSTIM; D 53; RIBOMUNYL; BRONCHO-VAXOM; CELL EXTRACT;

ADAPTIVE IMMUNITY; ASTHMA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED PRACTICE; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; MEDLINE; NOSE SMEAR; PATIENT-REPORTED OUTCOME; PHARMACOECONOMICS; PRACTICE GUIDELINE; RECURRENT DISEASE; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT INFECTION; REVIEW; ANIMAL; IMMUNOLOGY; PATHOPHYSIOLOGY; RESPIRATORY MUCOSA;

ANIMALS; ASTHMA; CELL EXTRACTS; HUMANS; IMMUNOMODULATION; RESPIRATORY MUCOSA; RESPIRATORY TRACT INFECTIONS;

EID: 85087771426     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1080/17476348.2020.1793673     Document Type: Review

References (49)

1. [1] Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;23:327–333.
2. [2] Diamond G, Legarda D, Ryan LK. The innate immune response of the respiratory epithelium. Immunol Rev. 2000;173:27–38.
3. [3] Scaglione F. OM-85 mechanism of action and efficacy in the prevention of the respiratory tract infections onset. Farm Aggiornamento Contin Prat Clin. 2017;16.
4. [4] Cardinale F, Bergamini M, Bernardini R, Capristo C, Fiore M, Martino S, Martire B, Moschese V, Simeone G, Soresina AR. Gli immunomodulanti nella prevenzione delle infezioni respiratorie del bambino: un approccio EBM. Riv Immunol E Allergol Pediatr. 2015;
5. [5] de la Torre González C, Pacheco Ríos A, Escalante Domínguez AJ, et al. [Comparative meta-analysis of immunoestimulant agents used in pediatric patients in Mexico]. Rev Alerg Mex Tecamachalco Puebla Mex 1993. 2005;52:25–38.
6. [6] Pasquali C, Salami O, Taneja M, et al. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Front Med. 2014;1:41.
7. [7] Tuvim MJ, Evans SE, Clement CG, et al. Augmented lung inflammation protects against influenza A pneumonia. PloS One. 2009;4:e4176.
8. [8] Evans SE, Scott BL, Clement CG, et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol. 2010;42:40–50.
9. [9] Dang AT, Pasquali C, Ludigs K, et al. OM-85 is an immunomodulator of interferon-β production and inflammasome activity. Sci Rep. 2017;7:43844.
10. [10] Duggan JM, You D, Cleaver JO, et al. Synergistic interactions of TLR2/6 and TLR9 induce a high level of resistance to lung infection in mice. J Immunol Baltim Md 1950. 2011;186:5916–5926.
11. [11] Luan H, Zhang Q, Wang L, et al. OM85-BV induced the productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-mediated ERK1/2/NF-κB pathway in RAW264.7 cells. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2014;34:526–536.
12. [12] Strickland DH, Judd S, Thomas JA, et al. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol. 2011;4:43–52.
13. [13] Parola C, Salogni L, Vaira X, et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PloS One. 2013;8:e82867.
14. [14] Roth M, Pasquali C, Stolz D, et al. Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP. PloS One. 2017;12:e0188010.
15. [15] Grüber C, Keil T, Kulig M, et al. History of respiratory infections in the first 12 yr among children from a birth cohort. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2008;19:505–512.
16. [16] Toivonen L, Karppinen S, Schuez-Havupalo L, et al. Burden of Recurrent Respiratory Tract Infections in Children: A Prospective Cohort Study. Pediatr Infect Dis J. 2016;35:e362–e369.
17. [17] von Linstow M-L, Holst KK, Larsen K, et al. Acute respiratory symptoms and general illness during the first year of life: a population-based birth cohort study. Pediatr Pulmonol. 2008;43:584–593.
18. [18] Kamper-Jørgensen M, Wohlfahrt J, Simonsen J, et al. Population-based study of the impact of childcare attendance on hospitalizations for acute respiratory infections. Pediatrics. 2006;118:1439–1446.
19. [19] de Martino M, Ballotti S. The child with recurrent respiratory infections: normal or not? Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2007;18 Suppl 18:13–18.
20. [20] Ambrosino DM, Umetsu DT, Siber GR, et al. Selective defect in the antibody response to Haemophilus influenzae type b in children with recurrent infections and normal serum IgG subclass levels. J Allergy Clin Immunol. 1988;81:1175–1179.
21. [21] Kutukculer N, Karaca NE, Demircioglu O, et al. Increases in serum immunoglobulins to age-related normal levels in children with IgA and/or IgG subclass deficiency. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2007;18:167–173.
22. [22] Casselbrant ML, Mandel EM, Fall PA, et al. The heritability of otitis media: a twin and triplet study. JAMA. 1999;282:2125–2130.
23. [23] Kvestad E, Kvaerner KJ, Røysamb E, et al. Heritability of recurrent tonsillitis. Arch Otolaryngol Head Neck Surg. 2005;131:383–387.
24. [24] Koch A, Melbye M, Sørensen P, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA. 2001;285:1316–1321.
25. [25] Wiertsema SP, Herpers BL, Veenhoven RH, et al. Functional polymorphisms in the mannan-binding lectin 2 gene: effect on MBL levels and otitis media. J Allergy Clin Immunol. 2006;117:1344–1350.
26. [26] Cardinale F, Chinellato I, Marseglia GL, et al. Prevalence of atopic symptoms among blood donor carriers of mannose-binding lectin variant alleles. Int J Immunopathol Pharmacol. 2008;21:735–738.
27. [27] Rye MS, Blackwell JM, Jamieson SE. Genetic susceptibility to otitis media in childhood. The Laryngoscope. 2012;122:665–675.
28. [28] Gutiérrez-Tarango MD, Berber A. Safety and efficacy of two courses of OM-85 BV in the prevention of respiratory tract infections in children during 12 months. Chest. 2001;119:1742–1748.
29. [29] Razi CH, Harmancı K, Abacı A, et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. J Allergy Clin Immunol. 2010;126:763–769.
30. [30] Schaad UB, Mütterlein R, Goffin H, et al. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest. 2002;122:2042–2049.
31. [31] Collet JP, Shapiro P, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med. 1997;156:1719–1724.
32. [32] Heintz B, Schlenter WW, Kirsten R, et al. Clinical efficacy of Broncho-Vaxom in adult patients with chronic purulent sinusitis–a multi-centric, placebo-controlled, double-blind study. Int J Clin Pharmacol. 1989;27:530–534.
33. [33] Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:3 p preceding table of contents, 1–298.
34. [34] Balachandran JS, Hall JB. Update in pulmonary, sleep, and critical care medicine: evidence published in 2013. Ann Intern Med. 2014;160:621–626.
35. [35] Regan KH, Hill AT. Emerging therapies in adult and paediatric bronchiectasis. Respirol Carlton Vic. 2018;23:1127–1137.
36. [36] Gao J, Gao X, Kong L. To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial. Trials. 2014;15:150.
37. [37] Holgate ST. Has the time come to rethink the pathogenesis of asthma? Curr Opin Allergy Clin Immunol. 2010;10:48–53.
38. [38] Plopper CG, Smiley-Jewell SM, Miller LA, et al. Asthma/allergic airways disease: does postnatal exposure to environmental toxicants promote airway pathobiology? Toxicol Pathol. 2007;35:97–110.
39. [39] Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18:673–683.
40. [40] Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007;357:1487–1495.
41. [41] Bisgaard H, Hermansen MN, Bønnelykke K, et al. Association of bacteria and viruses with wheezy episodes in young children: prospective birth cohort study. BMJ. 2010;341:c4978.
42. [42] Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PloS One. 2010;5:e8578.
43. [43] Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol. 2011;127:372-381.e1-3.
44. [44] Navarro S, Cossalter G, Chiavaroli C, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol. 2011;4:53–65.
45. [45] Zhang M, Luan H, Zhang Q, et al. Prevention of infection in immunosuppressive patients with autoimmune nephrosis by using an immunostimulating bacterial lysate Broncho-vaxom. Hum Vaccines Immunother. 2012;8:1802–1807.
46. [46] Capetti A, Cossu MV, Carenzi L, et al. Four years of immunization with OM-85 BV to prevent respiratory infections in HIV+ patients. Hum Vaccines Immunother. 2013;9:1849–1851.
47. [47] Berber A, Del-Rio-Navarro BE. Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers. Health Econ Rev. 2019;9:12.
48. [48] Ravasio R. Economic analysis of the immunostimulant OM-85 for the prevention of paediatric recurrent upper respiratory tract infections. Glob Reg Health Technol Assess. 2 (3). 2015;135–142.
49. [49] Han L, Zheng C-P, Sun Y-Q, et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy. 2014;28:110–116.